News & Updates

$Anifrolumab safe, effective in refractory SLE$

Anifrolumab safe, effective in refractory SLE

24 Nov 2024

Use of anifrolumab improves symptoms and induces remission in patients with refractory systemic lupus erythematosus (SLE), with an acceptable safety profile, a study has shown.

Anifrolumab safe, effective in refractory SLE

24 Nov 2024

Axial spondyloarthritis outcomes improved with intravenous secukinumab

09 Nov 2024 by

Intravenous (IV) secukinumab appears beneficial in the treatment of adults with active axial spondyloarthritis (axSpA), with improvements seen across disease activity, physical function, quality of life, and sleep measures, according to the results of the phase III INVIGORATE-1 trial.

Axial spondyloarthritis outcomes improved with intravenous secukinumab

09 Nov 2024

Virtual yoga classes show promise in chronic low back pain

09 Nov 2024

In the treatment of adults with chronic low back pain (LBP), virtual yoga classes are feasible, reducing pain intensity and improving sleep, according to a study.

Virtual yoga classes show promise in chronic low back pain

09 Nov 2024

Disabling foot pain in PsA: Marker of worse PsA, significant burden on daily life

07 Nov 2024 by

For Singaporeans with psoriatic arthritis (PsA), disabling foot pain appears to signal a more severe disease activity and exert a wide impact on daily life.

Disabling foot pain in PsA: Marker of worse PsA, significant burden on daily life

07 Nov 2024

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

06 Nov 2024 by

Compared with conventional therapies, exposure to tumour necrosis factor (TNF) inhibitors is associated with increased risk of inflammatory central nervous system (CNS) diseases, irrespective of background autoimmune disease or TNF inhibitor type, a recent meta-analysis has found.

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

06 Nov 2024

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

04 Nov 2024

In this article, Professor Tam discusses her management approach to optimising outcomes in patients with inflammatory arthritis. She explores the role of the treat-to-target approach, emphasizes the importance of early disease control in reducing cardiovascular risk and evaluates the benefit-risk analysis of upadacitinib.

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

04 Nov 2024

New gout diagnosis raises cardiovascular risk in the short term

27 Oct 2024

Individuals who have recently received a diagnosis of gout face an increased risk of cardiovascular events within 30 days of the index diagnosis, according to a study.

New gout diagnosis raises cardiovascular risk in the short term

27 Oct 2024

Reducing glucocorticoid use and organ-damage progression in SLE with early use of a B-lymphocyte stimulator antagonist

25 Oct 2024 by

A 20-year-old nulligravida female student, who was a nonsmoker and nondrinker with good past health, first presented in March 2024. She complained of significant alopecia and photosensitive rash that was slightly itchy but not painful, primarily affecting her face and hands for 2 months. She was generally well with no fever or joint pain, and no family history of rheumatological disorders.

Reducing glucocorticoid use and organ-damage progression in SLE with early use of a B-lymphocyte stimulator antagonist

25 Oct 2024

Multidisciplinary management of a patient with CRSwNP and comorbid asthma using add-on anti–IL-5

25 Oct 2024 by

A 60-year-old female nonsmoker was first diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbid asthma in 2003. (Table) Due to anosmia (loss of sense of smell), nasal congestion and postnasal drip, she underwent functional endoscopic sinus surgery (FESS) in 2013, which generally improved her symptoms. Tissue biopsy showed abundant eosinophils in nasal polyps. She used daily puffs of a budesonide/formoterol inhaler for asthma control. (Table)

Multidisciplinary management of a patient with CRSwNP and comorbid asthma using add-on anti–IL-5

25 Oct 2024

Verinurad–allopurinol combo disappoints in HFpEF

24 Oct 2024

Combining verinurad with allopurinol does not appear to boost oxygen uptake or improve symptoms in heart failure with preserved ejection fraction (HFpEF), despite yielding significant reductions in serum uric acid (SUA) levels, according to a phase II study.

Verinurad–allopurinol combo disappoints in HFpEF

24 Oct 2024

News & Updates

Filter by Specialty:

Specialty:

Anifrolumab safe, effective in refractory SLE

Anifrolumab safe, effective in refractory SLE

Axial spondyloarthritis outcomes improved with intravenous secukinumab

Axial spondyloarthritis outcomes improved with intravenous secukinumab

Virtual yoga classes show promise in chronic low back pain

Virtual yoga classes show promise in chronic low back pain

Disabling foot pain in PsA: Marker of worse PsA, significant burden on daily life

Disabling foot pain in PsA: Marker of worse PsA, significant burden on daily life

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

The role of treat-to-target in inflammatory arthritis: Addressing cardiovascular risk and evaluating the benefit-risk profile of upadacitinib

New gout diagnosis raises cardiovascular risk in the short term

New gout diagnosis raises cardiovascular risk in the short term

Reducing glucocorticoid use and organ-damage progression in SLE with early use of a B-lymphocyte stimulator antagonist

Reducing glucocorticoid use and organ-damage progression in SLE with early use of a B-lymphocyte stimulator antagonist

Multidisciplinary management of a patient with CRSwNP and comorbid asthma using add-on anti–IL-5

Multidisciplinary management of a patient with CRSwNP and comorbid asthma using add-on anti–IL-5

Verinurad–allopurinol combo disappoints in HFpEF

Verinurad–allopurinol combo disappoints in HFpEF